Previously, we identified a treatment regimen ("3+1") to synchronize and eradicate solid and ascites forms of murine Krebs-2 tumor. Using a similar strategy, we attempted to narrow down the treatment conditions for mouse hepatocarcinoma G-29 that can be passaged in mice as either ascites or solid grafts. We successfully developed the protocol that allowed elimination of the primary ascites. Our results indicate that the "3+1" treatment protocol wherein the final doses of cyclophosphamide and double-stranded DNA preparation are given on days 6 or 11 had the greatest therapeutic effect. Mean survival time was 36 days in treated mice vs 27 days in untreated controls. We further demonstrate that tightly scheduled cyclophosphamide treatment was in itself highly inhibitory to the growing G-29 ascites. It has been shown that in the case of ascitic form of G-29 tumor after synergistic action of cytostatic and double-stranded DNA preparation, secondary ascites arises following the appearance of peritoneal carcinomatous solid formation and, apparently, is its derivative.
|Number of pages||12|
|Publication status||Published - 1 Jan 2018|
- Double-stranded DNA
- Hepatocarcinoma G-29
- Secondary ascites